I was born in Oregon and raised in Iowa, where I cultivated my initial interest in science and medicine. I completed my undergraduate degree and medical school at the University of Iowa before heading to Stanford University for my internal medicine residency and oncology fellowship training. I chose this field to try my best in assisting patients during times of great need, and working to understand what is of greatest importance to them as they navigate their unique journey of cancer care. My scholarly interests include exploring both the efficacy and costs of novel cancer therapeutics, identifying important issues in patient survivorship, and promoting strength in medical education.
Honors & Awards
Timothy F. Beckett, Jr. Award for Best Clinical Teaching by a Medicine Fellow, Stanford University School of Medicine, Department of Internal Medicine (2018)
Award for Best Clinical Teaching by a Medicine Resident, Stanford University School of Medicine, Department of Internal Medicine (2017)
Charles Dorsey Armstrong Award for Clinical Excellence in Patient Care, Stanford University School of Medicine, Department of Internal Medicine (2017)
Julian Wolfsohn Award for Outstanding Performance in Internal Medicine, Stanford University School of Medicine, Department of Internal Medicine (2017)
Medical Student Education Award, Stanford University School of Medicine (2015)
William R. Wilson Award for Outstanding Performance in Internal Medicine by a Senior Medical Student, Carver College of Medicine, University of Iowa (2014)
Boards, Advisory Committees, Professional Organizations
Member, American Society of Clinical Oncology (2017 - Present)
Member, American Society of Hematology (2016 - Present)
Member, American College of Physicians (2014 - Present)
Residency, Stanford University, Internal Medicine (2017)
MD, Carver College of Medicine, University of Iowa (2014)
BS, University of Iowa, Biomedical Engineering (2010)
Thrombophilia testing in the inpatient setting: impact of an educational intervention.
BMC medical informatics and decision making
2019; 19 (1): 167
Thrombophilia testing is frequently ordered in the inpatient setting despite its limited impact on clinical decision-making and unreliable results in the setting of acute thrombosis or ongoing anticoagulation. We sought to determine the effect of an educational intervention in reducing inappropriate thrombophilia testing for hospitalized patients.During the 2014 academic year, we implemented an educational intervention with a phase implementation design for Internal Medicine interns at Stanford University Hospital. The educational session covering epidemiology, appropriate thrombophilia evaluation and clinical rationale behind these recommendations. Their ordering behavior was compared with a contemporaneous control (non-medicine and private services) and a historical control (interns from prior academic year). From the analyzed data, we determined the proportion of inappropriate thrombophilia testing of each group. Logistic generalized estimating equations were used to estimate odds ratios for inappropriate thrombophilia testing associated with the intervention.Of 2151 orders included, 934 were deemed inappropriate (43.4%). The two intervention groups placed 147 orders. A pooled analysis of ordering practices by intervention groups revealed a trend toward reduction of inappropriate ordering (p = 0.053). By the end of the study, the intervention groups had significantly lower rates of inappropriate testing compared to historical or contemporaneous controls.A brief educational intervention was associated with a trend toward reduction in inappropriate thrombophilia testing. These findings suggest that focused education on thrombophilia testing can positively impact inpatient ordering practices.
View details for DOI 10.1186/s12911-019-0889-6
View details for PubMedID 31429747
An Electronic Best Practice Alert Based on Choosing Wisely Guidelines Reduces Thrombophilia Testing in the Outpatient Setting.
Journal of general internal medicine
View details for PubMedID 30215176
The Power of Trust.
View details for PubMedID 29710067
- Trust in neuroendocrine tumors: The importance of communication in rare and chronic malignancies AMER SOC CLINICAL ONCOLOGY. 2018
Magnitude of Potentially Inappropriate Thrombophilia Testing in the Inpatient Hospital Setting.
Journal of hospital medicine
2017; 12 (9): 735–38
Laboratory costs of thrombophilia testing exceed an estimated $650 million (in US dollars) annually. Quantifying the prevalence and financial impact of potentially inappropriate testing in the inpatient hospital setting represents an integral component of the effort to reduce healthcare expenditures. We conducted a retrospective analysis of our electronic medical record to evaluate 2 years' worth of inpatient thrombophilia testing measured against preformulated appropriateness criteria. Cost data were obtained from the Centers for Medicare and Medicaid Services 2016 Clinical Laboratory Fee Schedule. Of the 1817 orders analyzed, 777 (42.7%) were potentially inappropriate, with an associated cost of $40,422. The tests most frequently inappropriately ordered were Factor V Leiden, prothrombin gene mutation, protein C and S activity levels, antithrombin activity levels, and the lupus anticoagulant. Potentially inappropriate thrombophilia testing is common and costly. These data demonstrate a need for institution-wide changes in order to reduce unnecessary expenditures and improve patient care.
View details for PubMedID 28914278
Prevalence and Financial Impact of Inappropriate Thrombophilia Testing in the Inpatient Hospital Setting: A Retrospective Analysis
AMER SOC HEMATOLOGY. 2016
View details for Web of Science ID 000394452508066